[1] Mocellin S, Marincola FM, Young HA. Interleukin-10 and the immune response against cancer:a counterpoint[J]. Journal of Leukocyte Biology, 2005, 78(5):1043-1051. [2] von Lanzenauer SH, Wolk K, Kunz S, et al. Interleukin-10 receptor-1 expression in monocyte-derived antigen-presenting cell populations:dendritic cells partially escape from IL-10’s inhibitory mechanisms[J]. Genes & Immunity, 2015, 16(1):8-14. [3] Trifunović J, Miller L, Debeljak Z, et al. Pathologic patterns of interleukin 10 expression a review[J]. Biochemia Medica, 2015, 25(1):36-48. [4] Kim R, Emi M, Tanabe K, et al. Tumor-driven evolution of immunosuppressive networks during malignant progression[J]. Cancer Research, 2006, 66(11):5527-5536. [5] Darnell JJ, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins[J]. Science, 1994, 264(5164):1415-1421. [6] Beser OF, Conde CD, Serwas NK, et al. Clinical features of interleukin 10 receptor gene mutations in children with very early-onset inflammatory bowel disease[J]. Journal of Pediatric Gastroenterology & Nutrition, 2014, 60(3):332-338. [7] Pestka S, Krause CD, Sarkar D, et al. Interleukin-10 and related cytokines and receptors[J]. Annual Review of Immunology, 2004, 22:929-979. [8] Commins S, Steinke JW, Borish L. The extended IL-10 superfamily:IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29[J]. Journal of Allergy & Clinical Immunology, 2008, 121(5):1108-1111. [9] Stelloo E, Versluis MA, Nijman HW, et al. Microsatellite instability derived JAK1 frameshift mutations are associated with tumor immune evasion in endometrioid endometrial cancer[J]. Oncotarget, 2016, 7(26):39885-39893. [10] Song B, Zhan H, Bian Q, et al. Piperlongumine inhibits gastric cancer cells via suppression of the JAK1, 2/STAT3 signaling pathway[J]. Molecular Medicine Reports, 2016, 13(5):4475-4480. [11] Li Q, Gu S, Li N, et al. Protein interaction network construction and biological pathway analysis related to atherosclerosis][J]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi, 2015, 32(6):1255-1260. [12] Verhelst J, De Vlieger D, Saelens X. Co-immunoprecipitation of the Mouse Mx1 Protein with the Influenza A Virus Nucleoprotein[J]. J Vis Exp, 2015(98):e52871. [13] Duan JW, Lu Z, Jiang B, et al. Discovery of pyrrolo[1, 2-b]pyridazine-3-carboxamides as Janus kinase(JAK)inhibitors[J]. Bioorganic & Medicinal Chemistry Letters, 2014, 24(24):5721-5726. [14] Einarson MB, Pugacheva EN, Orlinick JR. GST Pull-down[J]. CSH Protoc, 2007(2007):t4757. [15] Valero ML, Sendra R, Pamblanco M. Tandem affinity purification of histones, coupled to mass spectrometry, identifies associated proteins and new sites of post-translational modification in Saccharomyces cerevisiae[J]. J Proteomics, 2016, 136:183-192. [16] Saito Y, Nakagawa T, Kakihana A, et al. Yeast Two-Hybrid and One-Hybrid screenings identify regulators of hsp70 gene expression[J]. J Cell Biochem, 2016, 117(9):2109-2117. [17] Yu Y, Li Y, Zhang Y. Yeast Two-Hybrid screening for proteins that interact with the extracellular domain of amyloid precursor protein[J]. Neurosci Bull, 2016, 32(2):171-176. [18] Zhu Y, Chen X, Liu Z, et al. Interleukin-10 protection against lipopolysaccharide-induced neuro-inflammation and neurotoxicity in ventral mesencephalic cultures[J]. International Journal of Molecular Sciences, 2016, 17(1). [19] Wagner AH, Conzelmann M, Fitzer F, et al. JAK1/STAT3 activation directly inhibits IL-12 production in dendritic cells by preventing CDK9/P-TEFb recruitment to the p35 promoter[J]. Biochem Pharmacol, 2015, 96(1):52-64. |